Global Viral Conjunctivitis Drugs Market 2016-2020

Market outlook of the global viral conjunctivitis drugs market

Technavio’s research analyst predicts the global viral conjunctivitis drugs market to grow steadily at a CAGR of 2% during the forecast period. Growing awareness among consumers worldwide is the primary growth driver for this market. In conjunction with the developments in this market, many organizations have conducted awareness campaigns about this disease among the public. For instance, as part of the efforts of the Lebanese Ministry of Public Health, the Lebanese Ministry of Education and Higher Learning, the Faculty of Health Sciences of the University of Balamand conducted a conjunctivitis awareness campaign among the students, faculty and staff. Such programs increase the chances of identifying the infection, leading to an increased number of treatment-seeking patients, thereby boosting market growth during the forecast period.

The growing incidences of viral conjunctivitis are also expected to boost market growth during the forecast period. This type of conjunctivitis is more prevalent in adults than children. Viral conjunctivitis represents up to 50% of all acute conjunctivitis in primary care.

Segmentation by route of administration of the global viral conjunctivitis drugs market

• Topical
• Oral
• Intravitreal

Topical drugs are most commonly used for the treatment of viral conjunctivitis. Most of these drugs are used for viral conjunctivitis such as artificial tears, NSAIDs, steroids, and antihistamine drugs in the form of eye drops because of the ease of administration.

Geographical segmentation and analysis of the viral conjunctivitis drugs market

• Americas
• APAC
• EMEA

Americas accounted for approximately 49% of the market share in 2015, and it is expected to grow at a CAGR of 2% during the forecast period. A well-developed healthcare system, coupled with reimbursement facilities are the primary drivers of market growth in this region.

Competitive landscape and key vendors

The global viral conjunctivitis drugs market is highly fragmented because of the presence of numerous small and large vendors. Providers in this market compete on the basis of price, quality, and innovation. The high vendor competition has led to an increased number of mergers and acquisitions, wherein smaller entities are being acquired or are being merged with major players.

The leading vendors in the market are -

• Akorn
• Alcon
• Allergan
• Bausch & Lomb

Other prominent vendors in the market include Adenovir Pharma, Marinomed Biotechnologie, Mediolanum Laboratories, NanoViricides, Nicox, NovaBay, Novartis AG, PANOPTES PHARMA, Rapid Pathogen Screening, Shire, Star Pharma, and Valeant Pharmaceuticals.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the global viral conjunctivitis drugs market?
• What are the key market trends impacting the growth of the global viral conjunctivitis drugs market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the vendors in the global viral conjunctivitis drugs market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global viral conjunctivitis drugs market?

Technavio also offers customization on reports based on specific client requirement.

Related reports

• Global Conjunctivitis Market 2015-2019
• Global Ophthalmic Therapeutic Market 2015-2019
• Global Retinal Surgery Devices Market 2015-2019